ATP5F1B

Across TCGA pan-cancer cohorts, ATP5F1B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATP5F1B data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher ATP5F1B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ATP5F1B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRC, LIHC, and SARC are the cancer types where ATP5F1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRC	OS	Median	II,III,IV	0.203	0.789	.009	24	view →
LIHC	OS	Median	All	0.213	0.712	<.001	12	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
UCEC	OS	Median	All	1.000	0.662	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ATP5F1B–KIRC (OS)

Open the KIRC breakdown →